Maximum quantity allowed is 999
请选择数量
CAS RN: 366017-09-6 | 產品號碼: M3058
| 產品號碼 | M3058 |
純度/分析方法 
|
>98.0%(HPLC) |
| 分子式 / 分子量 | C__2__5H__2__3F__3N__4O__2 = 468.48 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Refrigerated (0-10°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器
|
25MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 366017-09-6 |
| Reaxys-RN | 13498857 |
| PubChem Substance ID | 354335238 |
| MDL編號 | MFCD09954135 |
產品規格
| Appearance | White to Gray to Brown powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 158.0 to 162.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 160 °C |
GHS
相關法規
運輸資料
| HS編碼* | 2934.99-000 |
Application
ヒト上皮成長因子受容体2 (HER2) チロシンキナーゼ阻害剤，ムブリチニブ
Small-molecule protein kinase inhibitors are widely used to elucidate cellular signaling pathways. Mubritinib (TAK 165) is a selective inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Reportedly, mubritinib specifically inhibits HER2 tyrosine kinase IC50 6 nmol/L and do not inhibit other types of tyrosine kinase up to 25,000 nmol/L.1) Several reports suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen-independent prostate cancer. However, the clinical development program for mubritinib as an anti-cancer drug was discontinued. (The product is for research purpose only.)
References
- 1)Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo
- 2)Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
考研文獻
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。